Skip to main content
PMC home page
British Journal of Pharmacology and Chemotherapy logoLink to British Journal of Pharmacology and Chemotherapy
. 1960 Mar;15(1):35–41. doi: 10.1111/j.1476-5381.1960.tb01207.x

The effect of iproniazid and imipramine on the blood platelet 5-hydroxytryptamine level in man

Elizabeth F Marshall, G S Stirling, A C Tait, A Todrick
PMCID: PMC1481980  PMID: 14421526

Abstract

Observations are reported on the blood platelet 5-hydroxytryptamine content of six patients receiving imipramine, N-(γ-dimethylaminopropyl)-iminodibenzyl hydrochloride. The response was a fall to a level of one-sixth of the original in three weeks, with little change thereafter. This is in sharp contrast to the action of iproniazid which caused a rise of some 200% in the blood platelet 5-hydroxytryptamine level over the same period. Imipramine in a concentration of 1 mg./ml. had no inhibitory action on 5-hydroxytryptophan decarboxylase; 8.0 μg./ml. of imipramine suppressed two-thirds of the in vitro uptake of 5-hydroxytryptamine (2.5 μg./ml.) by normal human platelets.

Full text

PDF
41

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMIN J., GRANT R. T. Further observations on vasoconstrictor substances in blood of rabbit and man. J Physiol. 1957 Oct 30;138(3):401–416. doi: 10.1113/jphysiol.1957.sp005858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BORN G. V., INGRAM G. I., STACEY R. S. The relationship between 5-hydroxytryptamine and adenosine triphosphate in blood platelets. Br J Pharmacol Chemother. 1958 Mar;13(1):62–64. doi: 10.1111/j.1476-5381.1958.tb00191.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BRADLEY P. B., KEY B. J. A comparative study of the effects of drugs on the arousal system of the brain. Br J Pharmacol Chemother. 1959 Sep;14:340–349. doi: 10.1111/j.1476-5381.1959.tb00254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BRILL H., PATTON R. E. Analysis of 1955-1956 population fall in New York State mental hospitals in first year of large-scale use of tranquilizing drugs. Am J Psychiatry. 1957 Dec;114(6):509–517. doi: 10.1176/ajp.114.6.509. [DOI] [PubMed] [Google Scholar]
  5. BRODIE B. B., TOMICH E. G., KUNTZMAN R., SHORE P. A. On the mechanism of action of reserpine: effect of reserpine on capacity of tissues to bind serotonin. J Pharmacol Exp Ther. 1957 Apr;119(4):461–467. [PubMed] [Google Scholar]
  6. Baar H. S. The Enumeration of Blood Platelets. J Clin Pathol. 1948 May;1(3):175–176. [PMC free article] [PubMed] [Google Scholar]
  7. CARLSSON A., SHORE P. A., BRODIE B. B. Release of serotonin from blood platelets by reserpine in vitro. J Pharmacol Exp Ther. 1957 Jul;120(3):334–339. [PubMed] [Google Scholar]
  8. DAVISON A. N., SANDLER M. Inhibition of 5-hydroxytryptophan decarboxylase by phenylalanine metabolites. Nature. 1958 Jan 18;181(4603):186–187. doi: 10.1038/181186b0. [DOI] [PubMed] [Google Scholar]
  9. DOMENJOZ R., THEOBALD W. [On the pharmacology of tofranil (N-(3-dimethylaminopropyl)-iminodibenzyl hydrochloride]. Arch Int Pharmacodyn Ther. 1959 Jul 1;120:450–489. [PubMed] [Google Scholar]
  10. FELDSTEIN A., HOAGLAND H., FREEMAN H. Blood and urinary serotonin and 5-hydroxyindole acetic acid levels in schizophrenic patients and normal subjects. J Nerv Ment Dis. 1959 Jul;129:62–68. doi: 10.1097/00005053-195907000-00007. [DOI] [PubMed] [Google Scholar]
  11. HARDISTY R. M., STACEY R. S. 5-Hydroxytryptamine in normal human platelets. J Physiol. 1955 Dec 29;130(3):711–720. doi: 10.1113/jphysiol.1955.sp005437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. HIMWICH H. E. Some drugs used in the treatment of mental disorders. Am J Psychiatry. 1959 Feb;115(8):756–759. doi: 10.1176/ajp.115.8.756. [DOI] [PubMed] [Google Scholar]
  13. HUMPHREY J. H., JAQUES R. The histamine and serotonin content of the platelets and polymorphonuclear leucocytes of various species. J Physiol. 1954 May 28;124(2):305–310. doi: 10.1113/jphysiol.1954.sp005109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. KIELHOLZ P., BATTEGAY R. Behandlung depressiver Zustandsbilder, Unterspezieller Berücksichtigung von Tofranil, einem neuen Antidepressivum. Schweiz Med Wochenschr. 1958 Aug 2;88(31):763–767. [PubMed] [Google Scholar]
  15. KUHN R. Uber die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz Med Wochenschr. 1957 Aug 31;87(35-36):1135–1140. [PubMed] [Google Scholar]
  16. MORSDORF K., BODE H. H. Zur Beeinflussung der permeabilitätssteigernden Wirkung des Serotonins durch verschiedenartige Pharmaka. Arch Int Pharmacodyn Ther. 1959 Feb 1;118(3-4):292–297. [PubMed] [Google Scholar]
  17. PARE C. M., SANDLER M. Acute hepatic necrosis following iproniazid therapy; value of glutamic-oxaloacetic transaminase estimation in early detection. Lancet. 1959 Feb 7;1(7067):282–284. doi: 10.1016/s0140-6736(59)90206-5. [DOI] [PubMed] [Google Scholar]
  18. PLETSCHER A., BERNSTEIN A. Increase of 5-hydroxytryptamine in blood platelets by isopropyl-isonicotinic acid hydrazide. Nature. 1958 Apr 19;181(4616):1133–1134. doi: 10.1038/1811133a0. [DOI] [PubMed] [Google Scholar]
  19. UDENFRIEND S., BOGDANSKI D. F., WEISSBACH H. Fluorescence characteristics of 5-hydroxytryptamine (serotonin). Science. 1955 Nov 18;122(3177):972–973. doi: 10.1126/science.122.3177.972. [DOI] [PubMed] [Google Scholar]
  20. UDENFRIEND S., WEISSBACH H., CLARK C. T. The estimation of 5-hydroxytryptamine (serotonin) in biological tissues. J Biol Chem. 1955 Jul;215(1):337–344. [PubMed] [Google Scholar]
  21. WEINER M., UDENFRIEND S. Relationship of platelet serotonin to disturbances of clotting and hemostasis. Circulation. 1957 Mar;15(3):353–357. doi: 10.1161/01.cir.15.3.353. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology and Chemotherapy are provided here courtesy of The British Pharmacological Society

RESOURCES